ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Intravenous iron (95% CI) Discontinuation: adverse events 304 VERY LOWa, b due to risk of bias, imprecision (from 78 fewer to 52 more) Ischaemic stroke 459 VERY LOWa, b due to risk of bias, imprecision Peto Odds (from 10 fewer to 20 more) Drug related vascular disorders (not defined) VERY LOWa, b, c due to risk of bias, indirectness, imprecision Peto Odds (from 20 fewer to 20 more) Gastrointestinal disorders (not defined) LOWa, b due to risk of bias, imprecision (from 2 fewer to 173 more) Drug related gastrointestinal disorders (not defined) VERY LOWa, b due to risk of bias, imprecision Peto Odds (from 10 fewer to 40 more) Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Intravenous iron (95% CI) LOWb due to imprecision (from 31 fewer to 471 more) Abdominal pain 60 LOWb due to imprecision Peto Odds (from 120 fewer to 50 more) Systolic blood pressure 60 MODERATEb due to imprecision The mean systolic blood pressure in the control groups was The mean systolic blood pressure in the intervention groups was (1.95 lower to 4.55 higher) (a) a Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias . (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MID. 